Entries by

Becton Dickinson, BioGX Partner To Submit COVID-19 Test For US Emergency Use

NEW YORK – Becton Dickinson and BioGX said on Monday that they have submitted a test to detect SARS-CoV-2, the virus that causes COVID-19, that runs on the BD Max system to the US Food and Drug Administration for Emergency Use Authorization. If authorized, the test could potentially increase screening capacity in the US.

BioGX Receives CE-IVD Mark For Enhanced Flu Assay

Amsterdam, The Netherlands, 22 October 2019 – BioGX B.V., the European subsidiary of Birmingham, Alabama based BioGX, announced it has received CE-IVD marking for its new Flu A, Flu B, RSV A/B automated test. The new test significantly enhances the strain coverage and detection sensitivity, and offers testing for a greater variety of specimen types compared […]

BioGX Launches Six CE-Mark Tests For Meningitis And Antibiotic Resistance

Amsterdam, The Netherlands, 24 May 2018 – BioGX B.V. continues its *BD MAX menu expansion with the launch of six additional CE-Mark infectious disease tests on Becton, Dickinson and Company’s BD MAX Sample-to-Answer platform. This brings the company’s CE-Mark menu for the BD MAX to eleven tests, with an additional ten planned for the second half […]

BioGX BV And AxonLab AG Announce Distribution Partnership

BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG.